Andrew C Gordon1,2, Sarah B White3, Yihe Yang4, Vanessa L Gates4, Daniel Procissi4, Kathleen R Harris4, Zhuoli Zhang4, Tianchu Lyu4, Xiaoke Huang4, Matthew R Dreher5, Reed A Omary6, Riad Salem4,7,8, Robert J Lewandowski4,7,8, Andrew C Larson4,9. 1. Department of Radiology, Northwestern University Feinberg School of Medicine, 737 N. Michigan Ave, 16th Floor, Chicago, IL, 60611, USA. andrew-gordon@northwestern.edu. 2. Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA. andrew-gordon@northwestern.edu. 3. Department of Radiology, Division of Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI, USA. 4. Department of Radiology, Northwestern University Feinberg School of Medicine, 737 N. Michigan Ave, 16th Floor, Chicago, IL, 60611, USA. 5. BTG International Inc, West Conshohocken, PA, USA. 6. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, USA. 7. Department of Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 8. Department of Surgery-Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 9. Department of Biomedical Engineering, Northwestern University, Evanston, IL, USA.
Abstract
PURPOSE: To evaluate the combination of 90Y radioembolization (Y90) and drug-eluting bead irinotecan (DEBIRI) microspheres in the VX2 rabbit model. MATERIALS AND METHODS: An initial dose finding study was performed in 6 White New Zealand rabbits to identify a therapeutic but subcurative dose of Y90. In total, 29 rabbits were used in four groups: Y90 treatment (n = 8), DEBIRI treatment (n = 6), Y90 + DEBIRI treatment (n = 7), and an untreated control group (n = 8). Hepatic toxicity was evaluated at baseline, 24 h, 72 h, 1 week, and 2 weeks. MRI tumor volume (TV) and enhancing tumor volume were assessed baseline and 2 weeks. Tumor area and necrosis were evaluated on H&E for pathology. RESULTS: Infused activities of 84.0-94.4 MBq (corresponding to 55.1-72.7 Gy) were selected based on the initial dose finding study. Infusion of DEBIRI after Y90 was technically feasible in all cases (7/7). Overall, 21/29 animals survived to 2 weeks, and the remaining animals had extrahepatic disease on necropsy. Liver transaminases were elevated with Y90, DEBIRI, and Y90 + DEBIRI compared to control at 24 h, 72 h, and 1 week post-treatment and returned to baseline by 2 weeks. By TV, Y90 + DEBIRI was the only treatment to show statistically significant reduction at 2 weeks compared to the control group (p = 0.012). The change in tumor volume (week 2-baseline) for both Y90 + DEBIRI versus control (p = 0.002) and Y90 versus control (p = 0.014) was significantly decreased. There were no statistically significant differences among groups on pathology. CONCLUSION: Intra-arterial Y90 + DEBIRI was safe and demonstrated enhanced antitumor activity in rabbit VX2 tumors. This combined approach warrants further investigation.
PURPOSE: To evaluate the combination of 90Y radioembolization (Y90) and drug-eluting bead irinotecan (DEBIRI) microspheres in the VX2 rabbit model. MATERIALS AND METHODS: An initial dose finding study was performed in 6 White New Zealand rabbits to identify a therapeutic but subcurative dose of Y90. In total, 29 rabbits were used in four groups: Y90 treatment (n = 8), DEBIRI treatment (n = 6), Y90 + DEBIRI treatment (n = 7), and an untreated control group (n = 8). Hepatic toxicity was evaluated at baseline, 24 h, 72 h, 1 week, and 2 weeks. MRI tumor volume (TV) and enhancing tumor volume were assessed baseline and 2 weeks. Tumor area and necrosis were evaluated on H&E for pathology. RESULTS: Infused activities of 84.0-94.4 MBq (corresponding to 55.1-72.7 Gy) were selected based on the initial dose finding study. Infusion of DEBIRI after Y90 was technically feasible in all cases (7/7). Overall, 21/29 animals survived to 2 weeks, and the remaining animals had extrahepatic disease on necropsy. Liver transaminases were elevated with Y90, DEBIRI, and Y90 + DEBIRI compared to control at 24 h, 72 h, and 1 week post-treatment and returned to baseline by 2 weeks. By TV, Y90 + DEBIRI was the only treatment to show statistically significant reduction at 2 weeks compared to the control group (p = 0.012). The change in tumor volume (week 2-baseline) for both Y90 + DEBIRI versus control (p = 0.002) and Y90 versus control (p = 0.014) was significantly decreased. There were no statistically significant differences among groups on pathology. CONCLUSION: Intra-arterial Y90 + DEBIRI was safe and demonstrated enhanced antitumor activity in rabbit VX2 tumors. This combined approach warrants further investigation.
Entities:
Keywords:
Chemoembolization; Irinotecan; Magnetic resonance imaging; Radioembolization; Yttrium-90
Authors: Guy A van Hazel; Volker Heinemann; Navesh K Sharma; Michael P N Findlay; Jens Ricke; Marc Peeters; David Perez; Bridget A Robinson; Andrew H Strickland; Tom Ferguson; Javier Rodríguez; Hendrik Kröning; Ido Wolf; Vinod Ganju; Euan Walpole; Eveline Boucher; Thomas Tichler; Einat Shacham-Shmueli; Alex Powell; Paul Eliadis; Richard Isaacs; David Price; Fred Moeslein; Julien Taieb; Geoff Bower; Val Gebski; Mark Van Buskirk; David N Cade; Kenneth Thurston; Peter Gibbs Journal: J Clin Oncol Date: 2016-02-22 Impact factor: 44.544
Authors: Robert C G Martin; Charles R Scoggins; Marshall Schreeder; William S Rilling; Christopher J Laing; Clifton M Tatum; Lawrence R Kelly; Ricardo D Garcia-Monaco; Vivek R Sharma; Todd S Crocenzi; Steven M Strasberg Journal: Cancer Date: 2015-07-06 Impact factor: 6.860
Authors: Giammaria Fiorentini; Camillo Aliberti; Massimo Tilli; Luca Mulazzani; Francesco Graziano; Paolo Giordani; Andrea Mambrini; Francesco Montagnani; Paolo Alessandroni; Vincenzo Catalano; Paolo Coschiera Journal: Anticancer Res Date: 2012-04 Impact factor: 2.480
Authors: Kent T Sato; Robert J Lewandowski; Mary F Mulcahy; Bassel Atassi; Robert K Ryu; Vanessa L Gates; Albert A Nemcek; Omar Barakat; Al Benson; Robert Mandal; Mark Talamonti; Ching-Yee O Wong; Frank H Miller; Steven B Newman; John M Shaw; Kenneth G Thurston; Reed A Omary; Riad Salem Journal: Radiology Date: 2008-03-18 Impact factor: 11.105
Authors: Robert C G Martin; Jonathan Joshi; Ken Robbins; Dana Tomalty; Petar Bosnjakovik; Milous Derner; Radek Padr; Miloslav Rocek; Alexander Scupchenko; Cliff Tatum Journal: Ann Surg Oncol Date: 2010-08-26 Impact factor: 5.344
Authors: Arthur J A T Braat; Julia E Huijbregts; I Quintus Molenaar; Inne H M Borel Rinkes; Maurice A A J van den Bosch; Marnix G E H Lam Journal: Front Oncol Date: 2014-07-30 Impact factor: 6.244
Authors: Tatjana Paunesku; Andrew C Gordon; Sarah White; Kathleen Harris; Olga Antipova; Evan Maxey; Stefan Vogt; Anthony Smith; Luiza Daddario; Daniele Procissi; Andrew Larson; Gayle E Woloschak Journal: Front Public Health Date: 2021-08-20